Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol. Oncol. 2003; 91(1):231-40.Bellone S,Palmieri M,Gokden M,et al.Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for He...
6.Antonino Musolino, Nadia Naldi, Beatrice Bortesi, et al. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer. J Clin Oncol ...
6. Antonino Musolino, Nadia Naldi, Beatrice Bortesi, et al. Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer....
Prevalence and Significance of HER-2/neu Amplification in Epithelial Ovarian Cancer AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002; ... Wong,Y.,F.,... - 《Gynecologic & Obstetric Investigati...
We evaluated 750 consecutive invasive breast carcinomas for HER-2/neu utilizing a combination of immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) methodologies. IHC reactions of 3+ were considered HER-2/neu positive and 0 and 1+ IHC reactions were considered HER-2/neu ...
“Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.” JAMA oncology vol. 7,4 (2021): 573-584. doi:10.1001/jamaoncol.2020.7932 Tesch, M.E., Gelmon, K.A. Targeting HER2 in Breast Cancer: Latest...
HER-2/ neu -positive tumor cells are potentially good targets for tumor-reactive cytotoxic T lymphocytes which have been utilized in immunotherapeutic trials. In addition, the "humanized" monoclonal antibody Herceptin has been tested in several clinical trials and proved to be an effective adjuvant ...
Xu B, Li W, Zhang Q, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020 Aug;182(3):68...
Of the 93 cases evaluable in both laboratories, 24% were scored as HER-2/neu–positive at 1 laboratory, and 23% were scored as positive at the other. Complete concordance in categorization of HER-2/neu status between the 2 laboratories was achieved in90 of 93 cases. Excellent ...
Patients with HER 2/neu positive expression were relatively older (mean age 62.5±17.08). However, there were equal in histopathological categorization (50% SCC and 50% Adenocarcinoma). Mean LDH was slightly higher in HER-2 positive patients was compared to HER-2 negative patients (569.5±232.6...